Entresto misses Phase III endpoint in new heart failure population

Novartis' hopes to expand the label of Entresto to include all heart failure patients took a hit Monday, when the pharma said the cardiovascular drug missed the primary endpoint in the Phase III PARAGON-HF study in patients

Read the full 370 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE